Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapy (Q45254298)
scientific article published on January 1, 1992
Language:
(P31) (Q13442814)
(P304) 50-55
(P407) (Q1860)
(P433) 1
(P478) 118
(P577) Wednesday, January 1, 1992
(P921) (Q162555)
(P953) http://link.springer.com/content/pdf/10.1007/BF01192311.pdf
http://link.springer.com/article/10.1007/BF01192311/fulltext.html
http://link.springer.com/content/pdf/10.1007/BF01192311
(P1433) (Q2081599)
(P1476) "Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapy" (language: en)
"Consideration of the use of 17 beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5- alpha-androstan-3-one (4MA), a 5 alpha-reductase inhibitor, in prostate cancer therapy" (language: en)
(P2093) A. A. Geldof
M. F. Meulenbroek
I. Dijkstra
S. Bohlken
B. R. Rao
(P2860) (Q69833760)
(Q70593557)
(Q70870392)
(Q43469186)
(Q69037749)
(Q44273226)
(Q71835384)
(Q69608371)
(Q70041708)
(Q68512926)
(Q71683778)
(Q68864709)
(Q70296570)
(Q70875329)
(Q70452977)
(Q70641009)
(Q38211611)
(Q400279)
other details
description scientific article published on January 1, 1992

External Links